A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy

  • Nawin KumarEmail author
  • Prabhat Kumar Sinha
  • Krishna Pandey
  • Neena Verma
  • Chandra Shekhar Lal
  • Alok Ranjan
  • Rakesh Bihari Verma
  • Pradeep Das
Case Report


Case We report a 32-year old relapse case of Visceral leishmaniasis, treated with Paromomycin who belonged from a endemic zone of Bihar state, India. After confirmation, he was treated with Amphotericin B, followed by Liposomal Amphotericin B in full course and even in higher dose. But after each therapy, the patient either did not responded or relapsed after treatment. Ultimately, the patient was successfully treated with combination therapy of Liposomal amphotericin B and Miltefosine without any relapse. Conclusion The multi-drug unresponsive Visceral leishmaniasis cases could pose a major threat to treatment strategy in the elimination program. In such situation, combination therapy seems to be a better approach that needs to be explored.


Visceral leishmaniasis Paromomycin Amphotericin B Liposomal amphotericin B Miltefosine Combination therapy 



The authors are thankful to the technical and nursing staffs for their support during the patient management.

Conflict of interest



  1. 1.
    Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a sub-clinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India. Clinical Infect Dis. 2000;31(4):1104–7.CrossRefGoogle Scholar
  3. 3.
    Jha TK, Giri YN, Singh TK, Jha S. Use of amphotericin-B in drug- resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Hyg. 1995;52:536–8.Google Scholar
  4. 4.
    Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral Leishmaniasis in India. New England J Med. 2007;356(25):2571–81.CrossRefGoogle Scholar
  5. 5.
    Jochim RC, Teixeira C. Leishmania commandeers the host inflammatory response through neutrohils. Trends Parasitol. 2009;25(4):145–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Alvar J, Aparicio P, Aseffa A, Boer MD, Cañavate C, Jean-Pierre Dedet, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334–59.PubMedCrossRefGoogle Scholar
  7. 7.
    Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis. 2009;48(2):e16–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Seifert K, Perez-Victoria FJ, Stettler M, Sanchez-Canete MP, Castanys S, Gamarro F, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistant that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents. 2007;30(3):229–35.PubMedCrossRefGoogle Scholar
  9. 9.
    Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, et al. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2010;105(2):115–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Sundar S, Sinha PK, Rai M, Verma DK, Kumar N, Alam S, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377(9764):477–86.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Nawin Kumar
    • 1
    Email author
  • Prabhat Kumar Sinha
    • 1
  • Krishna Pandey
    • 1
  • Neena Verma
    • 2
  • Chandra Shekhar Lal
    • 3
  • Alok Ranjan
    • 4
  • Rakesh Bihari Verma
    • 5
  • Pradeep Das
    • 6
  1. 1.Division of Clinical MedicineRMRIMS (ICMR)PatnaIndia
  2. 2.Division of PathologyRMRIMS (ICMR)PatnaIndia
  3. 3.Division of BiochemistryRMRIMS (ICMR)PatnaIndia
  4. 4.Division of Epidemiology & BiostatisticsRMRIMS (ICMR)PatnaIndia
  5. 5.Division of BiostatisticsRMRIMS (ICMR)PatnaIndia
  6. 6.Division of Molecular BiologyRMRIMS (ICMR)PatnaIndia

Personalised recommendations